{"record_key":"hexem-bio-inc","identifier":"hexem-bio-inc","external_key":"817020","title":"heXem bio Inc.","summary":null,"url":"https://inventions.pitt.edu/startups/hexem-bio-inc","json_url":"https://inventions.pitt.edu/startups/hexem-bio-inc.json","object_key":"startups","description":"heXem bio is developing therapies designed to restore the function of aging blood-forming stem cells. Its approach recreates a supportive early-development environment outside the body, aiming to rejuvenate the cells that replenish blood and immune systems. The initial program targets better bone marrow transplant outcomes for patients with blood cancer. [1]: https://hexemb.io/\nThe company's scientific foundation includes technology licensed from the University of Pittsburgh, connecting developmental biology with the pursuit of healthier aging. In 2026, heXem bio announced a $10.4 million seed round led by Draper Associates to advance its blood stem cell rejuvenation platform. [2]: https://pubmed.ncbi.nlm.nih.gov/42288505/ [3]: https://www.draper.vc/portfolio/hexembio","attributes":[{"key":"website","label":"Website","values":["https://hexemb.io/"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Immunology","Oncology"]},{"key":"funding_stage","label":"Funding Stage","values":["Seed"]},{"key":"founders","label":"Founders","values":["Gabriel Levesque Tremblay","Mo Ebrahimkhani","Samira Kiani","Joshua Hislop","Samet Yildirim"]}],"related":[]}